|
1
|
Rini BI, Campbell SC and Escudier B: Renal
cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
King SC, Pollack LA, Li J, King JB and
Master VA: Continued increase in incidence of renal cell carcinoma,
especially in young patients and high grade disease: United States
2001 to 2010. J Urol. 191:1665–1670. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ljungberg B, Bensalah K, Canfield S,
Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L,
Merseburger AS, et al: EAU guidelines on renal cell carcinoma: 2014
update. Eur Urol. 67:913–924. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Linehan WM and Ricketts CJ: Decade in
review-kidney cancer: Discoveries, therapies and opportunities. Nat
Rev Urol. 11:614–616. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Choueiri TK and Motzer RJ: Systemic
therapy for metastatic renal-cell carcinoma. N Engl J Med.
376:354–366. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Al-Baradie R, Yamada K, St Hilaire C, Chan
WM, Andrews C, McIntosh N, Nakano M, Martonyi EJ, Raymond WR,
Okumura S, et al: Duane radial ray syndrome (Okihiro syndrome) maps
to 20q13 and results from mutations in SALL4, a new member of the
SAL family. Am J Hum Genet. 71:1195–1199. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kohlhase J, Schuh R, Dowe G, Kühnlein RP,
Jäckle H, Schroeder B, Schulz-Schaeffer W, Kretzschmar HA, Köhler
A, Müller U, et al: Isolation, characterization, and organ-specific
expression of two novel human zinc finger genes related to the
Drosophila gene spalt. Genomics. 38:291–298. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tatetsu H, Kong NR, Chong G, Amabile G,
Tenen DG and Chai L: SALL4, the missing link between stem cells,
development and cancer. Gene. 584:111–119. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang J, Gao C, Chai L and Ma Y: A novel
SALL4/OCT4 transcriptional feedback network for pluripotency of
embryonic stem cells. PLoS One. 5:e107662010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rao S, Zhen S, Roumiantsev S, McDonald LT,
Yuan GC and Orkin SH: Differential roles of Sall4 isoforms in
embryonic stem cell pluripotency. Mol Cell Biol. 30:5364–5380.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cao D, Li J, Guo CC, Allan RW and Humphrey
PA: SALL4 is a novel diagnostic marker for testicular germ cell
tumors. Am J Surg Pathol. 33:1065–1077. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang L, Yan Y, Jiang Y, Cui Y, Zou Y,
Qian J, Luo C, Lu Y and Wu X: The expression of SALL4 in patients
with gliomas: High level of SALL4 expression is correlated with
poor outcome. J Neurooncol. 121:261–268. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cao D, Guo S, Allan RW, Molberg KH and
Peng Y: SALL4 is a novel sensitive and specific marker of ovarian
primitive germ cell tumors and is particularly useful in
distinguishing yolk sac tumor from clear cell carcinoma. Am J Surg
Pathol. 33:894–904. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mei K, Liu A, Allan RW, Wang P, Lane Z,
Abel TW, Wei L, Cheng H, Guo S, Peng Y, et al: Diagnostic utility
of SALL4 in primary germ cell tumors of the central nervous system:
A study of 77 cases. Mod Pathol. 22:1628–1636. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li A, Jiao Y, Yong KJ, Wang F, Gao C, Yan
B, Srivastava S, Lim GS, Tang P, Yang H, et al: SALL4 is a new
target in endometrial cancer. Oncogene. 34:63–72. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ushiku T, Shinozaki A, Shibahara J,
Iwasaki Y, Tateishi Y, Funata N and Fukayama M: SALL4 represents
fetal gut differentiation of gastric cancer, and is diagnostically
useful in distinguishing hepatoid gastric carcinoma from
hepatocellular carcinoma. Am J Surg Pathol. 34:533–540. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ma Y, Cui W, Yang J, Qu J, Di C, Amin HM,
Lai R, Ritz J, Krause DS and Chai L: SALL4, a novel oncogene, is
constitutively expressed in human acute myeloid leukemia (AML) and
induces AML in transgenic mice. Blood. 108:2726–2735. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu M, Yang F, Ren Z, Jiang Y, Ma Y, Chen Y
and Dai W: Identification of the nuclear localization signal of
SALL4B, a stem cell transcription factor. Cell Cycle. 13:1456–1462.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jeong HW, Cui W, Yang Y, Lu J, He J, Li A,
Song D, Guo Y, Liu BH and Chai L: SALL4, a stem cell factor,
affects the side population by regulation of the ATP-binding
cassette drug transport genes. PLoS One. 6:e183722011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang X, Yuan X, Zhu W, Qian H and Xu W:
SALL4: An emerging cancer biomarker and target. Cancer Lett.
357:55–62. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yong KJ, Chai L and Tenen DG: Oncofetal
gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med.
369:1171–1172. 2013.PubMed/NCBI
|
|
22
|
Zhang L, Xu Z, Xu X, Zhang B, Wu H, Wang
M, Zhang X, Yang T, Cai J, Yan Y, et al: SALL4, a novel marker for
human gastric carcinogenesis and metastasis. Oncogene.
33:5491–5500. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gao C, Dimitrov T, Yong KJ, Tatetsu H,
Jeong HW, Luo HR, Bradner JE, Tenen DG and Chai L: Targeting
transcription factor SALL4 in acute myeloid leukemia by
interrupting its interaction with an epigenetic complex. Blood.
121:1413–1421. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yong KJ, Li A, Ou WB, Hong CK, Zhao W,
Wang F, Tatetsu H, Yan B, Qi L, Fletcher JA, et al: Targeting SALL4
by entinostat in lung cancer. Oncotarget. 7:75425–75440. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
May M, Surcel C, Capitanio U, Dell'Oglio
P, Klatte T, Shariat S, Ecke T, Wolff I, Vergho D, Wagener N, et
al: Prognostic and discriminative power of the 7th TNM
classification for patients with surgically treated papillary renal
cell carcinoma: Results of a multi-institutional validation study
(CORONA subtype project). Scand J Urol. 51:269–276. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhai W, Sun Y, Guo C, Hu G, Wang M, Zheng
J, Lin W, Huang Q, Li G, Zheng J and Chang C: LncRNA-SARCC
suppresses renal cell carcinoma (RCC) progression via altering the
androgen receptor(AR)/miRNA-143-3p signals. Cell Death Differ.
24:1502–1517. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
He D, Li L, Zhu G, Liang L, Guan Z, Chang
L, Chen Y, Yeh S and Chang C: ASC-J9 suppresses renal cell
carcinoma progression by targeting an androgen receptor-dependent
HIF2α/VEGF signaling pathway. Cancer Res. 74:4420–4430. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Petejova N and Martinek A: Renal cell
carcinoma: Review of etiology, pathophysiology and risk factors.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 160:183–194.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ravaud A, Motzer RJ, Pandha HS, George DJ,
Pantuck AJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, et
al: Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after
Nephrectomy. N Engl J Med. 375:2246–2254. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ljungberg B, Albiges L, Abu-Ghanem Y,
Bensalah K, Dabestani S, Fernández-Pello S, Giles RH, Hofmann F,
Hora M, Kuczyk MA, et al: European association of urology
guidelines on renal cell carcinoma: The 2019 update. Eur Urol.
75:799–810. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rini BI and Atkins MB: Resistance to
targeted therapy in renal-cell carcinoma. Lancet Oncol.
10:992–1000. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pezaro C, Woo HH and Davis ID: Prostate
cancer: Measuring PSA. Intern Med J. 44:433–440. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang J: SALL4 as a transcriptional and
epigenetic regulator in normal and leukemic hematopoiesis. Biomark
Res. 6:12018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang L, Liu L, Gao H, Pinnamaneni JP,
Sanagasetti D, Singh VP, Wang K, Mathison M, Zhang Q, Chen F, et
al: The stem cell factor SALL4 is an essential transcriptional
regulator in mixed lineage leukemia-rearranged leukemogenesis. J
Hematol Oncol. 10:1592017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Farawela HM, Zawam HM, Al-Wakeel HA,
El-Nagdy MH, El-Refaey FA and Abdel-Rahman HA: Expression pattern
and prognostic implication of SALL4 gene in myeloid leukemias: A
case-control study. Scand J Clin Lab Invest. 79:65–70. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yakaboski E, Jares A and Ma Y: Stem cell
gene SALL4 in aggressive hepatocellular carcinoma: A cancer stem
cell-specific target? Hepatology. 60:419–421. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
He J, Zhou M, Chen X, Yue D, Yang L, Qin
G, Zhang Z, Gao Q, Wang D, Zhang C, et al: Inhibition of SALL4
reduces tumorigenicity involving epithelial-mesenchymal transition
via Wnt/β-catenin pathway in esophageal squamous cell carcinoma. J
Exp Clin Cancer Res. 35:982016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang J, Rao S, Chu J, Shen X, Levasseur
DN, Theunissen TW and Orkin SH: A protein interaction network for
pluripotency of embryonic stem cells. Nature. 444:364–368. 2006.
View Article : Google Scholar : PubMed/NCBI
|
